{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jiang C"],"funding":["Science and Technology Development Fund of Shanghai Pudong New Area","National Natural Science Foundation of China","Shanghai Scientific and Technological Innovation Program"],"pagination":["e2102500"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8529437"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(20)"],"pubmed_abstract":["Combinations of immune checkpoint therapies show encouraging results in the treatment of many human cancers. However, the higher costs and greater side effects of such combinations compared with single-agent immunotherapies limit their further applications. In this work, a novel smart agent, KN046@<sup>19</sup> F-ZIF-8, is developed to overcome these limitations. KN046 is a novel recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody-Fc fusion protein, which can bind to both PD-L1 and CTLA-4 effectively. ZIF-8 is a smart delivery system, which can safely and effectively deliver KN406 to a tumor. In vitro and in vivo results demonstrate that the smart agent KN046@<sup>19</sup> F-ZIF-8 not only improves the immune response rate of the antibody drug in treatment of tumors but al"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4."],"pmcid":["PMC8529437"],"funding_grant_id":["81771861","PKJ2020-Y55","81971648","19142202100"],"pubmed_authors":["He S","Qi M","Zhang J","Song S","Jiang C","Zhang L","Xu X","Tian Q"],"additional_accession":[]},"is_claimable":false,"name":"Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4.","description":"Combinations of immune checkpoint therapies show encouraging results in the treatment of many human cancers. However, the higher costs and greater side effects of such combinations compared with single-agent immunotherapies limit their further applications. In this work, a novel smart agent, KN046@<sup>19</sup> F-ZIF-8, is developed to overcome these limitations. KN046 is a novel recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody-Fc fusion protein, which can bind to both PD-L1 and CTLA-4 effectively. ZIF-8 is a smart delivery system, which can safely and effectively deliver KN406 to a tumor. In vitro and in vivo results demonstrate that the smart agent KN046@<sup>19</sup> F-ZIF-8 not only improves the immune response rate of the antibody drug in treatment of tumors but al","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-18T12:07:13.591Z","creation":"2025-05-18T12:07:13.591Z"},"accession":"S-EPMC8529437","cross_references":{"pubmed":["34473430"],"doi":["10.1002/advs.202102500"]}}